Celgene Corp (NASDAQ:CELG)
CAPS Rating:
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
RSS Headlines
Fool UK
Recs
Cash strong company (3.9B) with new revenue pipelines (Pomalyst, Apremilast, Abraxane (new apps) replacing Revlimid.